In the context of Alzheimer’s disease, amyloid-beta (Aβ) and tau proteins are considered endogenous biomarkers, that is, body-inherent substances whose altered abundance, modification state, or aggregation reflects pathological processes. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.